Ahmed Kayssi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ahmed Kayssi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Graham Roche-Nagle
University of Toronto; Division of Vascular Surgery; Eaton North, 6th Floor, Room EN 6-214 200 Elizabeth Street Toronto ON Canada M5G 2C4
4 shared publicationsDheeraj K Rajan
University of Toronto Division of Vascular and Interventional Radiology NCSB 1C‐553, 585 University Avenue Toronto Canada M5G 2N2
3 shared publicationsGeorge Oreopoulos
University of Toronto; Division of Vascular Surgery; Eaton North, 6th Floor, Room EN 6-214 200 Elizabeth Street Toronto ON Canada M5G 2C4
3 shared publications- Graham Roche-Nagle
Vascular Surgery, Toronto General Hospital, Toronto, Ontario, Canada
3 shared publications - Thomas L. Forbes
Division of Vascular Surgery, Peter Munk Cardiac Centre & University Health Network, University of Toronto, Toronto, Ontario, Canada
3 shared publications - Charles de Mestral
University of Toronto
2 shared publications
Latest Publications
- 19 January 2017
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (1)
Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries
- 19 January 2017
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (1)
Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries
- 1 January 2017
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 38, 293-297
Combined Coil Embolization and Foam Sclerotherapy for the Management of Varicose Veins
- 1 January 2017
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 38, 293-297
Combined Coil Embolization and Foam Sclerotherapy for the Management of Varicose Veins
- 4 August 2016
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2016 (8) , CD011319
Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs
Atherosclerotic peripheral arterial disease (PAD) can lead to disabling ischemia and limb loss. Treatment modalities have included risk factor optimization through life-style modifications and medications, or operative approaches using both open and minimally invasive techniques, such as balloon angioplasty. Drug-eluting balloon (DEB) angioplasty has emerged as a promising alternative to uncoated balloon angioplasty for the treatment of this difficult disease process. By ballooning and coating the inside of atherosclerotic vessels with cytotoxic agents, such as paclitaxel, cellular mechanisms responsible for atherosclerosis and neointimal hyperplasia are inhibited and its devastating complications are prevented or postponed. DEBs are considerably more expensive than uncoated balloons, and their efficacy in improving patient outcomes is unclear. To assess the efficacy of drug-eluting balloons (DEBs) compared with uncoated, nonstenting balloon angioplasty in people with symptomatic lower-limb peripheral arterial disease (PAD). The Cochrane Vascular Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched December 2015) and Cochrane Register of Studies (CRS) (2015, Issue 11). The TSC searched trial databases for details of ongoing and unpublished studies. We included all randomized controlled trials that compared DEBs with uncoated, nonstenting balloon angioplasty for intermittent claudication (IC) or critical limb ischemia (CLI). Two review authors (AK, TA) independently selected the appropriate trials and performed data extraction, assessment of trial quality, and data analysis. The senior review author (DKR) adjudicated any disagreements. Eleven trials that randomized 1838 participants met the study inclusion criteria. Seven of the trials included femoropopliteal arterial lesions, three included tibial arterial lesions, and one included both. The trials were carried out in Europe and in the USA and all used the taxane drug paclitaxel in the DEB arm. Nine of the 11 trials were industry-sponsored. Four companies manufactured the DEB devices (Bard, Bavaria Medizin, Biotronik, and Medtronic). The trials examined both anatomic and clinical endpoints. There was heterogeneity in the frequency of stent deployment and the type and duration of antiplatelet therapy between trials. Using GRADE assessment criteria, the quality of the evidence presented was moderate for the outcomes of target lesion revascularization and change in Rutherford category, and high for amputation, primary vessel patency, binary restenosis, death, and change in ankle-brachial index (ABI). Most participants were followed up for 12 months, but one trial reported outcomes at five years. There were better outcomes for DEBs for up to two years in primary vessel patency (odds ratio (OR) 1.47, 95% confidence interval (CI) 0.22 to 9.57 at six months; OR 1.92, 95% CI 1.45 to 2.56 at 12 months; OR 3.51, 95% CI 2.26 to 5.46 at two years) and at six months and two years for late lumen loss (mean difference (MD) -0.64 mm, 95% CI -1.00 to -0.28 at six months; MD -0.80 mm, 95% CI -1.44 to -0.16 at two years). DEB were also superior to uncoated balloon angioplasty for up to five years in target lesion revascularization (OR 0.28, 95% CI 0.17 to 0.47 at six months; OR 0.40, 95% CI 0.31 to 0.51 at 12 months; OR 0.28, 95% CI 0.18 to 0.44 at two years; OR 0.21, 95% CI 0.09 to 0.51 at five years) and binary restenosis rate (OR 0.44, 95% CI 0.29 to 0.67 at six months; OR 0.38, 95% CI 0.15 to 0.98 at 12 months; OR 0.26, 95% CI 0.10 to 0.66 at two years; OR 0.12, 95% CI 0.05 to 0.30 at five years). There was no significant difference between DEB and uncoated angioplasty in amputation, death, change in ABI, change in Rutherford category and quality of life (QoL) scores, or functional walking ability, although none of the trials were powered to detect a significant difference in these clinical endpoints. We carried out two subgroup analyses to examine outcomes in femoropopliteal and tibial interventions as well as in people with CLI (4 or greater Rutherford class), and showed no advantage for DEBs in tibial vessels at six and 12 months compared with uncoated balloon angioplasty. There was also no advantage for DEBs in CLI compared with uncoated balloon angioplasty at 12 months. Based on a meta-analysis of 11 trials with 1838 participants, there is evidence of an advantage for DEBs compared with uncoated balloon angioplasty in several anatomic endpoints such as primary vessel patency (high-quality evidence), binary restenosis rate (moderate-quality evidence), and target lesion revascularization (low-quality evidence) for up to 12 months. Conversely, there is no evidence of an advantage for DEBs in clinical endpoints such as amputation, death, or change in ABI, or change in Rutherford category during 12 months' follow-up. Well-designed randomized trials with long-term follow-up are needed to compare DEBs with uncoated balloon angioplasties adequately for both anatomic and clinical study endpoints before the widespread use of this expensive technology can be justified.
- 4 August 2016
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2016 (8) , CD011319
Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs
Atherosclerotic peripheral arterial disease (PAD) can lead to disabling ischemia and limb loss. Treatment modalities have included risk factor optimization through life-style modifications and medications, or operative approaches using both open and minimally invasive techniques, such as balloon angioplasty. Drug-eluting balloon (DEB) angioplasty has emerged as a promising alternative to uncoated balloon angioplasty for the treatment of this difficult disease process. By ballooning and coating the inside of atherosclerotic vessels with cytotoxic agents, such as paclitaxel, cellular mechanisms responsible for atherosclerosis and neointimal hyperplasia are inhibited and its devastating complications are prevented or postponed. DEBs are considerably more expensive than uncoated balloons, and their efficacy in improving patient outcomes is unclear. To assess the efficacy of drug-eluting balloons (DEBs) compared with uncoated, nonstenting balloon angioplasty in people with symptomatic lower-limb peripheral arterial disease (PAD). The Cochrane Vascular Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched December 2015) and Cochrane Register of Studies (CRS) (2015, Issue 11). The TSC searched trial databases for details of ongoing and unpublished studies. We included all randomized controlled trials that compared DEBs with uncoated, nonstenting balloon angioplasty for intermittent claudication (IC) or critical limb ischemia (CLI). Two review authors (AK, TA) independently selected the appropriate trials and performed data extraction, assessment of trial quality, and data analysis. The senior review author (DKR) adjudicated any disagreements. Eleven trials that randomized 1838 participants met the study inclusion criteria. Seven of the trials included femoropopliteal arterial lesions, three included tibial arterial lesions, and one included both. The trials were carried out in Europe and in the USA and all used the taxane drug paclitaxel in the DEB arm. Nine of the 11 trials were industry-sponsored. Four companies manufactured the DEB devices (Bard, Bavaria Medizin, Biotronik, and Medtronic). The trials examined both anatomic and clinical endpoints. There was heterogeneity in the frequency of stent deployment and the type and duration of antiplatelet therapy between trials. Using GRADE assessment criteria, the quality of the evidence presented was moderate for the outcomes of target lesion revascularization and change in Rutherford category, and high for amputation, primary vessel patency, binary restenosis, death, and change in ankle-brachial index (ABI). Most participants were followed up for 12 months, but one trial reported outcomes at five years. There were better outcomes for DEBs for up to two years in primary vessel patency (odds ratio (OR) 1.47, 95% confidence interval (CI) 0.22 to 9.57 at six months; OR 1.92, 95% CI 1.45 to 2.56 at 12 months; OR 3.51, 95% CI 2.26 to 5.46 at two years) and at six months and two years for late lumen loss (mean difference (MD) -0.64 mm, 95% CI -1.00 to -0.28 at six months; MD -0.80 mm, 95% CI -1.44 to -0.16 at two years). DEB were also superior to uncoated balloon angioplasty for up to five years in target lesion revascularization (OR 0.28, 95% CI 0.17 to 0.47 at six months; OR 0.40, 95% CI 0.31 to 0.51 at 12 months; OR 0.28, 95% CI 0.18 to 0.44 at two years; OR 0.21, 95% CI 0.09 to 0.51 at five years) and binary restenosis rate (OR 0.44, 95% CI 0.29 to 0.67 at six months; OR 0.38, 95% CI 0.15 to 0.98 at 12 months; OR 0.26, 95% CI 0.10 to 0.66 at two years; OR 0.12, 95% CI 0.05 to 0.30 at five years). There was no significant difference between DEB and uncoated angioplasty in amputation, death, change in ABI, change in Rutherford category and quality of life (QoL) scores, or functional walking ability, although none of the trials were powered to detect a significant difference in these clinical endpoints. We carried out two subgroup analyses to examine outcomes in femoropopliteal and tibial interventions as well as in people with CLI (4 or greater Rutherford class), and showed no advantage for DEBs in tibial vessels at six and 12 months compared with uncoated balloon angioplasty. There was also no advantage for DEBs in CLI compared with uncoated balloon angioplasty at 12 months. Based on a meta-analysis of 11 trials with 1838 participants, there is evidence of an advantage for DEBs compared with uncoated balloon angioplasty in several anatomic endpoints such as primary vessel patency (high-quality evidence), binary restenosis rate (moderate-quality evidence), and target lesion revascularization (low-quality evidence) for up to 12 months. Conversely, there is no evidence of an advantage for DEBs in clinical endpoints such as amputation, death, or change in ABI, or change in Rutherford category during 12 months' follow-up. Well-designed randomized trials with long-term follow-up are needed to compare DEBs with uncoated balloon angioplasties adequately for both anatomic and clinical study endpoints before the widespread use of this expensive technology can be justified.
- 1 November 2015
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 62 (5) , 1383
Risk-Modifying Medication Prescription and Compliance in Vascular Surgery Patients
- 1 November 2015
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 62 (5) , 1383
Risk-Modifying Medication Prescription and Compliance in Vascular Surgery Patients
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (4) , S183
Rehabilitation Outcomes after Lower-Extremity Amputations in Canada
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (4) , S183
Rehabilitation Outcomes after Lower-Extremity Amputations in Canada
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (4) , S177
Combined Coil Embolization and Foam Sclerotherapy for the Management of Varicose Veins: Description of a Novel Technique
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (4) , S177
Combined Coil Embolization and Foam Sclerotherapy for the Management of Varicose Veins: Description of a Novel Technique
- Open Access
- 1 September 2015
- Published by Elsevier in Journal of Vascular Surgery Cases
- Vol. 1 (3) , 217-220
Management of acute limb ischemia after glue embolization of endoleak following endovascular abdominal aortic aneurysm repair
- 1 September 2015
- Published by Elsevier in Journal of Vascular Surgery Cases
- Vol. 1 (3) , 217-220
Open AccessManagement of acute limb ischemia after glue embolization of endoleak following endovascular abdominal aortic aneurysm repair
- 1 August 2015
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 62 (2) , 491-498
Health-related quality-of-life outcomes after open versus endovascular abdominal aortic aneurysm repair
- 1 August 2015
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 62 (2) , 491-498
Health-related quality-of-life outcomes after open versus endovascular abdominal aortic aneurysm repair
- 1 June 2015
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 61 (6) , 86S
Antiplatelet Therapy Prescription Patterns After Lower Limb Angioplasty in Canada: Results From a National Survey
- 1 June 2015
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 61 (6) , 86S
Antiplatelet Therapy Prescription Patterns After Lower Limb Angioplasty in Canada: Results From a National Survey
- 1 June 2015
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 61 (6) , 132S
PC54. Predictors of Hospital Readmissions after Lower Extremity Amputations in Canada
- 1 June 2015
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 61 (6) , 132S
PC54. Predictors of Hospital Readmissions after Lower Extremity Amputations in Canada